Cartalax 20mg

$39.99

Quick Overview:  Observations from preclinical literature. 

  • May support fibroblast proliferation and reduce markers of cellular senescence in aged cell cultures. 
  • Preclinical data suggest modulation of extracellular matrix homeostasis via MMP‑9 inhibition and collagen‑related gene expression. 
  • Khavinson bioregulator peptides have been described in observational reports; safety in humans has not been established by regulatory review. 
  • Limitations: No large‑scale human RCTs; most data derive from in vitro or rodent models. 

NOTE: This content is intended for educational purposes only and does not constitute medical advice, any diagnosis, or any treatment. This is strictly a research use only compound and not approved by regulatory agencies for human or veterinary therapeutic use or application.  

In stock

TitleRangeDiscount
Quantity tiers2 5%
Quantity tiers3 7.5%
Quantity tiers4 10%
Quantity tiers5 + 12.5%
SKU: CARTX-20MG-1V Categories: , Tag:
Extra Features
  • 3rd-Party Lab Tested
  • Encrypted Checkout (SSL)

Scientific Overview:

Cartalax (Ala‑Glu‑Asp) is classified among the Khavinson bioregulatory peptides—ultrashort peptides that may interact with DNA and modulate gene expression at nanomolar concentrations. The peptide sequence corresponds to a motif found in the alpha‑1 chain of type XI collagen, a structural protein important for cartilage integrity. In preclinical fibroblast and chondrocyte culture models, Cartalax has been reported to upregulate Ki‑67 (a proliferation marker), increase SIRT‑1/SIRT‑6 expression, reduce p53 and caspase‑3 activity (pro‑apoptotic signals), and inhibit MMP‑9 synthesis (an enzyme linked to extracellular matrix degradation).


NOTE: This content is intended for educational purposes only and does not constitute medical advice, any diagnosis, or any treatment. This is strictly a research use only compound and not approved by regulatory agencies for human or veterinary therapeutic use or application.